Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, 4 Royal College Street, NW1 0TU, London, United Kingdom.
Department of Comparative Biomedical Sciences, The Royal Veterinary College, University of London, 4 Royal College Street, NW1 0TU, London, United Kingdom; Consortium for Mitochondrial Research (CfMR), University College London, Gower Street, WC1E 6BT, London, United Kingdom; Department of Biology, University of Rome TorVergata, Via della Ricerca Scientifica, Rome, 00133, Italy.
EBioMedicine. 2021 Mar;65:103244. doi: 10.1016/j.ebiom.2021.103244. Epub 2021 Feb 26.
Mitochondria play a vital role in cellular metabolism and are central mediator of intracellular signalling, cell differentiation, morphogenesis and demise. An increasingly higher number of pathologies is linked with mitochondrial dysfunction, which can arise from either genetic defects affecting core mitochondrial components or malfunctioning pathways impairing mitochondrial homeostasis. As such, mitochondria are considered an important target in several pathologies spanning from neoplastic to neurodegenerative diseases as well as metabolic syndromes. In this review we provide an overview of the state-of-the-art in mitochondrial pharmacology, focusing on the novel compounds that have been generated in the bid to correct mitochondrial aberrations. Our work aims to serve the scientific community working on translational medical science by highlighting the most promising pharmacological approaches to target mitochondrial dysfunction in disease.
线粒体在细胞代谢中起着至关重要的作用，是细胞内信号转导、细胞分化、形态发生和死亡的中心介质。越来越多的病理学与线粒体功能障碍有关，线粒体功能障碍可能源于影响核心线粒体成分的遗传缺陷，也可能源于破坏线粒体动态平衡的功能失调途径。因此，线粒体被认为是从肿瘤到神经退行性疾病以及代谢综合征等多种病理学的重要靶点。在这篇综述中，我们概述了线粒体药理学的最新进展，重点介绍了为纠正线粒体异常而产生的新型化合物。我们的工作旨在为从事转化医学科学的科学界提供服务，突出针对疾病中线粒体功能障碍的最有前途的药理学方法。
